EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance.

The lack of effective tumor-associated antigens restricts the development of targeted therapies against myeloid leukemia. In this study, we compared gene expression patterns of acute myeloid leukemia (AML) and normal bone marrow samples and found that epithelial cell adhesion molecule (EpCAM) is frequently overexpressed in patients with AML, with EpCAM+ leukemic cells exhibiting enhanced chemoresistance and oncogenesis. The chemotherapeutic resistance of EpCAM-positive leukemic cells is a consequence of increased WNT5B signaling. Furthermore, we generated EpCAM antibodies that enabled phagocytosis or cytotoxicity of AML cells by macrophage or natural killer cells, respectively. Finally, EpCAM antibody treatment depleted AML in subcutaneous, disseminated, and intramedullary engrafted mice. In summary, EpCAM exhibits promise as a novel target for the treatment of leukemia. Cancer Res; 77(2); 482-93. ©2016 AACR.

[1]  Mark A. Dawson,et al.  BET inhibitor resistance emerges from leukaemia stem cells , 2015, Nature.

[2]  R. Sun,et al.  TLR2 limits development of hepatocellular carcinoma by reducing IL18-mediated immunosuppression. , 2015, Cancer research.

[3]  Xiaohu Zheng,et al.  Targeting LUNX inhibits non-small cell lung cancer growth and metastasis. , 2015, Cancer research.

[4]  B. Calabretta,et al.  Leukemia stem cells: Old concepts and new perspectives. , 2014, Molecular aspects of medicine.

[5]  Binqing Fu,et al.  Molecular signatures and transcriptional regulatory networks of human immature decidual NK and mature peripheral NK cells , 2014, European journal of immunology.

[6]  M. Kahn,et al.  The role of the Wnt signaling pathway in cancer stem cells: prospects for drug development , 2014, Research and reports in biochemistry.

[7]  M. Hemann,et al.  Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy , 2014, Cell.

[8]  Xiang Gao,et al.  Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. , 2013, The Journal of clinical investigation.

[9]  Binqing Fu,et al.  IGF-1 promotes the development and cytotoxic activity of human NK cells , 2013, Nature Communications.

[10]  B. Wilson,et al.  Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies , 2013, Leukemia.

[11]  O. Hammer.  CD19 as an attractive target for antibody-based therapy , 2012, mAbs.

[12]  B. Huntly,et al.  Recent advances in acute myeloid leukemia stem cell biology , 2012, Haematologica.

[13]  H. Rammensee,et al.  Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia , 2012, Leukemia.

[14]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[15]  Louis M. Weiner,et al.  Antibody-Based Immunotherapy of Cancer , 2012, Cell.

[16]  Binqing Fu,et al.  TGF-β1 Down-Regulation of NKG2D/DAP10 and 2B4/SAP Expression on Human NK Cells Contributes to HBV Persistence , 2012, PLoS pathogens.

[17]  H. Mellstedt,et al.  Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. , 2012, Cancer treatment reviews.

[18]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[19]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[20]  M. Carroll,et al.  Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. , 2011, The Journal of clinical investigation.

[21]  J. Fagerberg,et al.  Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies , 2010, Cancer Cell International.

[22]  I. Weissman,et al.  Macrophages as mediators of tumor immunosurveillance. , 2010, Trends in immunology.

[23]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[24]  Andrew C. Chan,et al.  Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.

[25]  P. Murawa,et al.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial , 2010, International journal of cancer.

[26]  Wolfram Goessling,et al.  The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML , 2010, Science.

[27]  S. Millar,et al.  Wnt/β-catenin Signaling in Oral Tissue Development and Disease , 2010, Journal of dental research.

[28]  C. Cavard,et al.  EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. , 2010, Journal of hepatology.

[29]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[30]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[31]  O. Gires,et al.  On the abundance of EpCAM on cancer stem cells , 2009, Nature Reviews Cancer.

[32]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[33]  M. Cheng,et al.  Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer , 2008, BMC Cancer.

[34]  R. Kimmig,et al.  Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study , 2007, Clinical Cancer Research.

[35]  O. Gires,et al.  EpCAM (CD326) finding its role in cancer , 2007, British Journal of Cancer.

[36]  Hans Clevers,et al.  Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.

[37]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[38]  D. Scheinberg,et al.  Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195 , 2003, Leukemia.

[39]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[40]  S. Litvinov,et al.  The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.

[41]  M. Hennig,et al.  Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). , 2012, Cancer research.

[42]  B. Chabner,et al.  Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.